Application of traditional Chinese medicine composition in preparation of medicine for treating and / or preventing bronchitis

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of medicines for treating and / or preventing bronchitis. The traditional Chinese medicine composition is prepared from 5-30 parts of herba houttuyniae, 5-30 parts of honeysuckle flowers, 5-20 parts of radix paeoniae rubra, 3-15 parts of folium artemisiae argyi and 3-15 parts of herba menthae. It is found that the composition can significantly reduce the content of serum inflammatory factors IL-1beta and IL-2 of LPS-induced chronic bronchitis model rats; the traditional Chinese medicine composition can obviously prolong the cough latency period of a model mouse with the chronic bronchitis caused by smoking, reduce the cough frequency and inhibit serum IL-1beta secretion, so that the traditional Chinese medicine composition has the effects of relieving cough and resisting inflammation and has a good treatment effect on the bronchitis.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicines, and in particular to the use of a traditional Chinese medicine composition in preparing medicines for treating and / or preventing bronchitis. Background Art

[0002] Bronchitis is an inflammatory disease involving the bronchial mucosa, which mainly causes symptoms such as coughing, expectoration and difficulty breathing. The causes of this disease are varied, including but not limited to bacterial infection, environmental stimulation and personal lifestyle habits. In the process of treating bronchitis, drug therapy is a major treatment method, which has significant therapeutic effects, but it also comes with some advantages and disadvantages.

[0003] The advantage of drug treatment is that it is fast and effective. For bronchitis, doctors usually prescribe cough suppressants, expectorants, anti-inflammatory and anti-infective drugs. These drugs can directly act on inflammation and bacteria, effectively relieve coughs, clear sputum, and inhibit the reproduction of bacteria, thereby quickly alleviating the patient's pain. In addition, with the deepening of medical research, the types of drugs and treatment methods are constantly being updated, making the treatment effect more significant.

[0004] However, drug treatment also has some disadvantages. First, drug side effects are an issue that cannot be ignored. Some cough and expectorant drugs may cause digestive discomfort such as nausea and vomiting, while anti-inflammatory and anti-infective drugs may affect liver and kidney function. In addition, long-term and large-scale use of antibiotics may also lead to increased drug resistance of bacteria, making treatment more difficult. Secondly, drug treatment cannot fundamentally solve the problem of bronchitis. Although drugs can relieve symptoms, bronchitis may still recur if lifestyle is not improved and contact with pathogenic factors is avoided.

[0005] At present, Chinese patent medicine preparations have been widely used in the treatment of different types of bronchitis. However, according to the current clinical situation, there is still a need for better drugs to play a role in the treatment of bronchitis. Summary of the invention

[0006] In view of this, the technical problem to be solved by the present invention is to provide an application of a Chinese medicine composition in the preparation of a drug for treating and / or preventing bronchitis.

[0007] The present invention provides the use of a Chinese medicine composition in preparing a medicine for preventing and treating bronchitis;

[0008] The Chinese medicine composition comprises the following raw materials in parts by weight: 5-30 parts of houttuynia cordata, 5-30 parts of honeysuckle, 5-20 parts of red peony root, 3-15 parts of wormwood leaves, and 3-15 parts of mint.

[0009] In the present invention, the prevention and treatment includes: reducing the level of inflammatory factors.

[0010] Inflammatory factors play an important role in the pathogenesis of bronchitis. In the case of bronchitis, excessive production of inflammatory factors may lead to an aggravated inflammatory response of the bronchial mucosa, manifested as symptoms such as coughing and expectoration. At the same time, inflammatory factors may also cause contraction of bronchial smooth muscles, leading to airway stenosis and dyspnea. Experiments of the present invention show that the Chinese medicine composition as described above can reduce the level of inflammatory factors. In some embodiments, the inflammatory factors are inflammatory factors in serum. More specifically, the inflammatory factors include IL-1β and / or IL-2.

[0011] In the present invention, the bronchitis is bronchitis caused by harmful gases and / or bronchitis caused by lung inflammation.

[0012] In some embodiments, the harmful gas is cigarette smoke.

[0013] In some embodiments, the lung inflammation is LPS-induced lung inflammation.

[0014] In an embodiment of the present invention, the mass fractions of each component in the traditional Chinese medicine composition are: 5-25 parts of houttuynia cordata, 5-25 parts of honeysuckle, 5-15 parts of red peony root, 3-10 parts of wormwood, and 3-10 parts of mint. Furthermore, the mass fractions of each component in the traditional Chinese medicine composition are: 15-25 parts of houttuynia cordata, 15-25 parts of honeysuckle, 10-15 parts of red peony root, 5-10 parts of wormwood, and 3-5 parts of mint.

[0015] Optionally, the mass proportions of each component in the traditional Chinese medicine composition are: 20 parts of Houttuynia cordata, 20 parts of Honeysuckle, 12 parts of Red Peony Root, 8 parts of Artemisia argyi, and 4 parts of mint.

[0016] Optionally, the mass proportions of each component in the traditional Chinese medicine composition are: 15 parts of Houttuynia cordata, 15 parts of Honeysuckle, 12 parts of Red Peony Root, 7 parts of Artemisia argyi, and 7 parts of mint.

[0017] Optionally, the mass proportions of each component in the traditional Chinese medicine composition are: 10 parts of Houttuynia cordata, 10 parts of Honeysuckle, 8 parts of Red Peony Root, 4 parts of Artemisia argyi, and 4 parts of Mint.

[0018] The composition of the present invention can be directly ground into powder, or it can be an extract obtained by conventional means in the art. The composition can be directly ground into powder by conventional methods, or it can be an extract obtained by conventional means, so as to be made into different dosage forms, obtain better therapeutic effects and be more conducive to the preparation of modern pharmaceutical dosage forms.

[0019] In an embodiment of the present invention, the preparation method of the Chinese medicine composition comprises:

[0020] Step A: weighing Chinese medicinal materials according to the weight ratio of the raw materials;

[0021] Step B: extracting honeysuckle with 6-12 times the amount of 50%-80% ethanol, filtering the extract, recovering the ethanol, drying and crushing to obtain a dry paste powder;

[0022] Step C: add 3-12 times of water to Houttuynia cordata, Artemisia argyi and mint to extract volatile oil, add coarse powder of red peony root to the residue, add 6-12 times of water to boil, filter the extract to obtain a clear paste, add ethanol with a concentration of more than 90% to 60% to 80% alcohol, precipitate with alcohol, let stand, recover ethanol from the supernatant to obtain a thick paste, dry and crush to obtain dry paste powder;

[0023] Step D: Mix the volatile oil and the two dry paste powders.

[0024] Furthermore, the method for preparing the Chinese medicine composition comprises the following steps:

[0025] Step A: Add 12 times the amount of 50% ethanol to honeysuckle, reflux extract twice, each time for 0.5 hours, filter, combine the filtrate, recover the ethanol under reduced pressure and concentrate to a thick paste with a relative density of 1.20 to 1.25, dry under reduced pressure, and crush to obtain alcohol-extracted dry extract powder;

[0026] Step B: add 8 times the amount of water to Houttuynia cordata, Artemisia argyi and mint, extract volatile oil by steam distillation for 5 hours, filter the extract and set aside;

[0027] Step C: grinding and inclusion of the obtained volatile oil with 10 times the amount of β-cyclodextrin and 20 times the amount of water for 20 minutes, drying and crushing the inclusion compound to obtain a volatile oil inclusion compound;

[0028] Step D: after extracting the volatile oil, the residue is combined with red peony root, 10 times the amount of water is added, extraction is performed twice, each time for 1 hour, the extract is combined with the oil extraction liquid, filtered, the filtrate is concentrated under reduced pressure to a clear paste with a relative density of 1.02-1.05, cooled to room temperature, 95% ethanol is added to make the alcohol content reach 70%, and the mixture is allowed to stand for more than 12 hours. The supernatant of the alcohol precipitation is reduced in pressure to recover ethanol and concentrated to a thick paste with a relative density of 1.25-1.30, dried under reduced pressure, and crushed to obtain a water-extracted dry extract powder; the alcohol-extracted dry extract powder, the volatile oil inclusion compound and the water-extracted dry extract powder are mixed.

[0029] The present invention also provides a medicine for bronchitis, which comprises pharmaceutically acceptable excipients and the following raw materials in parts by weight: 5-30 parts of houttuynia cordata, 5-30 parts of honeysuckle, 5-20 parts of red peony root, 3-15 parts of wormwood leaf, and 3-15 parts of mint.

[0030] The dosage forms of the drug of the present invention include, but are not limited to, decoctions, tablets, capsules, granules, pills, injections, decoctions, suspensions, dispersions, syrups, suppositories, gels, aerosols, patches and / or oral solutions.

[0031] In some embodiments provided by the present invention, the capsule is a hard capsule or a soft capsule.

[0032] In some embodiments provided herein, the tablet is an oral tablet or an oral tablet.

[0033] Oral tablets refer to tablets for oral administration. Most of the drugs in such tablets are absorbed through the gastrointestinal tract to exert their effects, and some of the drugs in tablets exert their effects locally in the gastrointestinal tract. In some embodiments provided by the present invention, the oral tablets are ordinary compressed tablets, dispersible tablets, effervescent tablets, chewable tablets, coated tablets or sustained-release tablets.

[0034] The pharmaceutically acceptable excipients include one or a mixture of two or more of fruit powder, edible flavors, sweeteners, acidulants, fillers, lubricants, preservatives, suspending agents, edible pigments, diluents, emulsifiers, disintegrants or plasticizers.

[0035] The medicine described in the present invention also includes other medicines for preventing and treating bronchitis, and the other medicines for preventing and treating bronchitis include: at least one of budesonide, fluticasone, prednisone, dexamethasone, salmeterol, formoterol, salbutamol, terbutaline, montelukast sodium, zafirlukast, cetirizine, loratadine, aminophylline, and ipratropium bromide.

[0036] In the present invention, in the medicine, the Chinese medicine composition and other therapeutic agents may exist independently of each other or may exist in combination, and the present invention does not limit this.

[0037] Furthermore, the present invention also provides a method for preventing and treating bronchitis, which comprises administering the drug of the present invention.

[0038] The administration methods of the drug include, but are not limited to, oral administration, spray inhalation, rectal administration, nasal administration, buccal administration, vaginal administration, topical administration. Or non-enteral administration, such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal or intracranial injection or infusion; or administration via an explanted reservoir. Preferably, the administration method is oral administration and / or aerosol inhalation.

[0039] In the present invention, when the medicine includes a Chinese medicine composition and other therapeutic agents, two or more medicines can be administered simultaneously or sequentially, and the present invention is not limited to this.

[0040] For example, the Chinese medicine composition in the medicine is administered no longer than 6 hours, preferably no longer than 5 hours, more preferably no longer than 4 hours, even more preferably no longer than 3 hours, more preferably no longer than 2 hours and most preferably no longer than 1 hour before the administration of other therapeutic agents and / or no longer than 6 hours, preferably no longer than 5 hours, more preferably no longer than 4 hours, even more preferably no longer than 3 hours, more preferably no longer than 2 hours and most preferably no longer than 1 hour after the administration of other therapeutic agents.

[0041] In the present invention, when the medicine includes a Chinese medicine composition and other therapeutic agents, the administration frequency of two or more medicines may be the same or different, and the present invention is not limited to this.

[0042] For example, the administration frequency of two or more of the drugs is independently selected from 4 times / day, 3 times / day, 2 times / day or 1 time / day, wherein the administration frequency of the Chinese medicine composition is 4 times / day, 3 times / day, 2 times / day or 1 time / day.

[0043] In the present invention, the medicine includes a Chinese medicine composition, and the dosage is not less than the effective dose. If the medicine includes a Chinese medicine composition and other therapeutic agents, the dosage of the Chinese medicine composition is lower than the effective dose, or not lower than the effective dose; the dosage of other therapeutic agents is lower than the effective dose, or not lower than the effective dose.

[0044] In the present invention, the effective dose includes a "therapeutically effective amount" or a "prophylactically effective amount", which refers to an amount that is sufficient to treat or prevent a patient's disease but low enough to avoid serious side effects (at a reasonable benefit / risk ratio) within the scope of reasonable medical judgment. The preventive or therapeutic effective amount of a drug will vary depending on the specific drug selected (e.g., considering the efficacy, effectiveness and half-life of the drug), the selected route of administration, the disease to be prevented or treated, the severity of the disease to be prevented or treated, the age, size, weight and physical illness of the patient to be prevented or treated, the medical history of the patient to be prevented or treated, the duration of prevention or treatment, the nature of concurrent therapy, the desired preventive or therapeutic effect, and other factors, but can still be routinely determined by those skilled in the art.

[0045] In the present invention, the prevention and treatment includes prevention and / or treatment, which is a preventive and therapeutic measure for bronchitis. This includes a method for preventing the occurrence of bronchitis, the purpose of which is to prevent, slow down (reduce) undesirable physiological changes or lesions in the treated subject, and the beneficial or desired clinical results include but are not limited to avoiding the occurrence of bronchitis, alleviating bronchitis symptoms, reducing the degree of bronchitis, stabilizing the bronchitis state (i.e., not worsening), delaying or slowing the progression of bronchitis, improving or alleviating the bronchitis state, and alleviating (whether partial or complete), whether detectable or undetectable. Subjects in need of treatment include subjects who already have a condition or disease, as well as subjects who are susceptible to a condition or disease or subjects who intend to prevent a condition or disease.

[0046] In the present invention, the object of prevention and treatment is a human or a mammal, and the mammal includes bovines, equines, ovines, swine, canines, felines, rodents, and primates. The rodent is a mouse and / or a rat.

[0047] The Chinese medicine composition of the present invention comprises 5-30 parts of houttuynia cordata, 5-30 parts of honeysuckle, 5-20 parts of red peony root, 3-15 parts of wormwood leaf and 3-15 parts of mint. The present invention finds that the composition can significantly reduce the content of serum inflammatory factors IL-1β and IL-2 in rats with chronic bronchitis model induced by LPS; can significantly prolong the cough latency of mice with chronic bronchitis model induced by smoke, reduce the number of coughs, and inhibit the secretion of serum IL-1β, indicating that the Chinese medicine composition has antitussive and anti-inflammatory effects and has a good therapeutic effect on bronchitis. DETAILED DESCRIPTION

[0048] The present invention provides the use of a Chinese medicine composition in the preparation of a medicine for treating and / or preventing bronchitis. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0049] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0050] The present invention will be further described below in conjunction with embodiments:

[0051] Example 1 Preparation of Chinese medicine composition granules

[0052] Ratio of raw materials: Houttuynia cordata: 750g, honeysuckle 750g, red peony root 450g, wormwood leaf 300g, mint 150g.

[0053] Step A: adding 12 times the amount of 50% ethanol to honeysuckle, reflux extraction twice, each time for 0.5 hour, filtering, combining the filtrate, reducing pressure (-0.07MPa to -0.09MPa, 65°C to 75°C) to recover ethanol and concentrate to a thick paste with a relative density of 1.20 to 1.25 (65°C), reducing pressure drying (-0.07MPa to -0.09MPa, 60°C to 65°C), and crushing to obtain alcohol-extracted dry extract powder;

[0054] Step B: add 8 times the amount of water to Houttuynia cordata, Artemisia argyi and mint, and extract volatile oil by steam distillation for 5 hours, filter the extract, and store it in another container for standby use;

[0055] Step C: grinding and inclusion of the obtained volatile oil with 10 times the amount of β-cyclodextrin and 20 times the amount of water for 20 minutes, drying the inclusion compound (55° C.), and crushing to obtain a volatile oil inclusion compound;

[0056] Step D: after extracting the volatile oil, the residue is combined with red peony root, 10 times the amount of water is added, and extraction is performed twice, each time for 1 hour. The extract is combined with the oil extraction liquid, filtered, and the filtrate is concentrated under reduced pressure (-0.07MPa to -0.09MPa, 75°C to 85°C) to a clear paste with a relative density of 1.02 to 1.05 (70°C), cooled to room temperature, and 95% ethanol is added to make the alcohol content reach 70%, and the mixture is allowed to stand for more than 12 hours. The supernatant of the alcohol precipitation is decompressed (-0.07MPa to -0.09MPa, 65°C to 75°C) to recover ethanol and concentrate to a thick paste with a relative density of 1.25 to 1.30 (65°C), and an appropriate amount of dextrin is added to reduce the pressure (-0.07MPa to -0.09MPa, 75°C) to dry, and pulverize to obtain a water-extracted dry extract powder.

[0057] The above three intermediates (dry extract powder of alcohol extraction part, volatile oil inclusion compound, dry extract powder of water extraction part) are mixed with appropriate amount of dextrin and stevioside, and dry granulated to prepare 1000g granules.

[0058] Example 2 Effect of Chinese medicine composition on chronic bronchitis rat model

[0059] 1. Experimental Materials

[0060] 1.1 Animals

[0061] Wistar rats, SPF grade, weighing 170-190g, half male and half female. Rearing environment: room temperature 20-25℃, relative humidity controlled at 40-70%, rearing density 5 rats / cage.

[0062] 1.2 Drugs and reagents

[0063] Chinese medicine composition, three intermediates prepared according to the method of Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.; Ketaling capsules (produced by Baiyunshan Pharmaceutical General Factory of Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., batch number 4140079). Lipopolysaccharide (LPS, Sigma, USA, item number L2630); rat interleukin-1β (IL-1β, Elabscience, item number: E-EL-R0012); rat interleukin 2 (IL-2) enzyme-linked immunosorbent assay kit, Wuhan Beiyinlai Biotechnology Co., Ltd., item number: RA20132).

[0064] 1.3 Instruments

[0065] Electronic balance (Sartorius Scientific Instruments, model BS224S); low-temperature centrifuge (eppendorf, Germany, model 5804R); animal weighing scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); microplate reader (Megu Molecular, USA, model Flexstation 3).

[0066] 2. Dosage design

[0067] The daily dosage of the Chinese medicine composition is 72g of crude drug / day. According to the body surface area conversion method, the rat equivalent dose is 72 / 60×6.2=7.44g of crude drug / kg. Taking this dose as the middle dose and designing it according to the ratio of 1 / 2:1:2, the low dose is 3.72g of crude drug / kg and the high dose is 14.88g of crude drug / kg.

[0068] The clinical daily dosage of Ketaling Capsules is 1.08g. According to the body surface area conversion method, the equivalent dose for rats is 1.08g / 60kg×6.2=0.112g / kg.

[0069] 3. Experimental Methods

[0070] 70 Wistar rats were selected, 10 of which were used as blank control group, half of which were male and half were female; the remaining 60 rats were anesthetized and the trachea was exposed, and LPS was instilled intratracheally using a 1mL syringe, 200μg / rat (1mg / mL). The blank control group was also instilled with the same volume of saline. After instillation, the drug was evenly distributed in both lungs, the wound was sutured, and the rats were fed routinely for 21 days. On the 22nd day, the modeling animals were randomly divided into 5 groups according to body weight, namely, model control group, Ketaling capsule group, low-dose, medium-dose, and high-dose groups of traditional Chinese medicine composition, with 10 rats in each group, half of which were male and half were female. Each group was given the corresponding drug by gavage at 10mL / kg, and the blank control group and model control group were gavaged with pure water, once a day, for 21 consecutive days. After the end of the administration, the rats were anesthetized, blood was collected from the abdominal aorta, and serum was collected by centrifugation at 3500r / min. The ELISA kit was used to detect the levels of IL-1β and IL-2 in serum.

[0071] 4. Statistical methods

[0072] The results were statistically analyzed using t-test.

[0073] 5. Experimental Results

[0074] 5.1 Effects on IL-1β and IL-2 levels in serum of rats with chronic bronchitis

[0075] Compared with the blank control group, the serum IL-1β and IL-2 levels in the model control group were significantly increased (P<0.01); compared with the model control group, the IL-1β and IL-2 levels in the Ketaling capsule group and each dose group of the Chinese medicine composition were significantly reduced (P<0.05, P<0.01). The results are shown in Table 1.

[0076] Table 1 Effects on serum IL-1β and IL-2 levels in rats with chronic bronchitis

[0077]

[0078] Note: Compared with the blank control group, ##P<0.01; compared with the model control group, *P<0.05, **P<0.01.

[0079] 6. Experimental conclusion

[0080] The Chinese medicine composition can significantly reduce the levels of serum inflammatory factors IL-1β and IL-2 in rats with chronic bronchitis, indicating that the Chinese medicine composition has a certain anti-inflammatory effect on rats with LPS-induced chronic bronchitis.

[0081] Example 3 Effect of Chinese herbal medicine composition on mice with chronic bronchitis induced by smoke

[0082] 1. Experimental Materials

[0083] 1.1 Animals

[0084] Balb / c mice, 50, male, SPF grade, weighing 18-22 g, were purchased from the Comparative Medicine Center of Yangzhou University, license number: SCXK (Su) 2022-0009. Breeding environment: room temperature 20-25°C, relative humidity controlled at 40-70%, and breeding density of 5 mice / cage.

[0085] 1.2 Drugs and reagents

[0086] Chinese medicine composition, three intermediates prepared according to the method of Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.; Feining Granules, Xiuzhen Pharmaceutical Group Co., Ltd.; mouse interleukin-1β (IL-1β, Elabscience, product number: E-EL-M0037).

[0087] 1.3 Instruments

[0088] Electronic balance (Sartorius Scientific Instruments, model BS224S); animal weighing scale (Shanghai Xiangchuan Electronic Scale Co., Ltd., model: CX-SC-DA); microplate reader (American Meigu Molecular, model Flexstation 3);

[0089] 2. Dosage design

[0090] The daily dosage of the Chinese medicine composition is 72g of crude drug / day. According to the body surface area conversion method, the equivalent dose for mice is 72 / 60×12.3=14.76g of crude drug / kg. According to the 1 / 2:1:2 dosing method, the low dose is 7.38g of crude drug / kg and the high dose is 29.52g of crude drug / kg.

[0091] The clinical daily dosage of Feining Granules is 30g. According to the body surface area conversion method, the equivalent dose for mice is 30g / 60kg×12.3=6.15g / kg.

[0092] 3. Experimental Methods

[0093] After 5 days of adaptive feeding, the mice were randomly divided into 5 groups according to their body weight, namely, model control group, Feining granule group, low-dose, medium-dose and high-dose groups of Chinese medicine composition, with 10 mice in each group. Each group was given the corresponding drug by gavage at a volume of 20 mL / kg, once a day, and the administration lasted for 21 days. 40 minutes after the first administration, the mice were placed in a self-made transparent fumigation device with a volume of 10-20 m3, and cigarettes were burned by an automatic smoking device, and the smoke was passed into the fumigation box so that the smoke concentration reached 4% within 2 minutes, and the fumigation lasted for 30 minutes. For the first 10 days, the mice were fumigated twice a day, with an interval of 4 hours each time. After 10 days, the mice were fumigated once a day to prepare a mouse model of chronic bronchitis caused by cigarette fumigation. 40 minutes after the last administration, the mice were placed in the fumigation device, and the smoke was injected into the fumigation box. The latency of the first cough and the number of coughs within 3 minutes of the mice were observed. The next day, the mice were anesthetized and blood was taken, centrifuged at 3500r / min, and serum was collected. The ELISA kit was used to detect the IL-1β content in serum.

[0094] 4. Statistical methods

[0095] The results were statistically analyzed using t-test.

[0096] 5. Experimental Results

[0097] 5.1 Effects on cough and serum IL-1β levels in mice with chronic bronchitis

[0098] Compared with the model control group, the high dose of Feining granules and Chinese medicine combination can significantly prolong the cough latency of mice (P<0.05); each dose group of Feining granules and Chinese medicine combination can significantly reduce the number of coughs in mice and reduce the serum IL-1β content (P<0.05, P<0.01). The results are shown in Table 2.

[0099] Table 2 Effects on cough and serum IL-1β in mice with chronic bronchitis

[0100]

[0101] Note: Compared with the model control group, *P<0.05, **P<0.01.

[0102] 6. Experimental conclusion

[0103] The Chinese medicine composition can significantly alleviate the cough symptoms of chronic bronchitis mice and reduce the serum IL-1β content, indicating that the Chinese medicine composition has antitussive and anti-inflammatory effects on the smoke-induced chronic bronchitis model in mice and has a certain therapeutic effect.

[0104] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of a Chinese medicine composition in the preparation of a drug for preventing and treating bronchitis; The Chinese medicine composition comprises the following raw materials in parts by weight: 5-30 parts of houttuynia cordata, 5-30 parts of honeysuckle, 5-20 parts of red peony root, 3-15 parts of wormwood leaves, and 3-15 parts of mint.

2. The use according to claim 1, characterized in that: The prevention and treatment includes: reducing the level of inflammatory factors.

3. The use according to claim 2, characterized in that: The inflammatory factors include IL-1β and / or IL-2.

4. The use according to claim 2, characterized in that: The inflammatory factors are inflammatory factors in serum.

5. The use according to any one of claims 1 to 4, characterized in that: The bronchitis is bronchitis caused by harmful gases and / or bronchitis caused by lung inflammation.

6. The use according to claim 5, characterized in that: The harmful gas is cigarette smoke, and the lung inflammation is lung inflammation caused by LPS.

7. The use according to any one of claims 1 to 6, characterized in that: The preparation method of the Chinese medicine composition comprises: Step A: weighing Chinese medicinal materials according to the weight ratio of the raw materials; Step B: extracting honeysuckle with 6-12 times the amount of 50%-80% ethanol, filtering the extract, recovering the ethanol, drying and crushing to obtain a dry paste powder; Step C: add 3-12 times of water to Houttuynia cordata, Artemisia argyi and mint to extract volatile oil, add coarse powder of red peony root to the residue, add 6-12 times of water to boil, filter the extract to obtain a clear paste, add ethanol with a concentration of more than 90% to 60% to 80% alcohol, precipitate with alcohol, let stand, recover ethanol from the supernatant to obtain a thick paste, dry and crush to obtain dry paste powder; Step D: Mix the volatile oil and the two dry paste powders.

8. The use according to claim 7, characterized in that: The method for preparing the Chinese medicine composition comprises the following steps: Step A: Add 12 times the amount of 50% ethanol to honeysuckle, reflux extract twice, each time for 0.5 hours, filter, combine the filtrate, recover the ethanol under reduced pressure and concentrate to a thick paste with a relative density of 1.20 to 1.25, dry under reduced pressure, and crush to obtain alcohol-extracted dry extract powder; Step B: add 8 times the amount of water to Houttuynia cordata, Artemisia argyi and mint, extract volatile oil by steam distillation for 5 hours, filter the extract and set aside; Step C: grinding and inclusion of the obtained volatile oil with 10 times the amount of β-cyclodextrin and 20 times the amount of water for 20 minutes, drying and crushing the inclusion compound to obtain a volatile oil inclusion compound; Step D: after extracting the volatile oil, the residue is combined with red peony root, 10 times the amount of water is added, extraction is performed twice, each time for 1 hour, the extract is combined with the oil extraction liquid, filtered, the filtrate is concentrated under reduced pressure to a clear paste with a relative density of 1.02-1.05, cooled to room temperature, 95% ethanol is added to make the alcohol content reach 70%, and the mixture is allowed to stand for more than 12 hours. The supernatant of the alcohol precipitation is reduced in pressure to recover ethanol and concentrated to a thick paste with a relative density of 1.25-1.30, dried under reduced pressure, and crushed to obtain a water-extracted dry extract powder; the alcohol-extracted dry extract powder, the volatile oil inclusion compound and the water-extracted dry extract powder are mixed.

9. A drug for preventing and treating chronic obstructive pulmonary disease, characterized in that: The invention comprises pharmaceutically acceptable auxiliary materials and the following raw materials in parts by weight: 5-30 parts of houttuynia cordata, 5-30 parts of honeysuckle, 5-20 parts of red peony root, 3-15 parts of wormwood leaf and 3-15 parts of mint.

10. The drug according to claim 9, characterized in that The invention also includes other therapeutic agents for bronchitis, which include at least one of fresh bamboo sap liquid, Ketaling, Feining granules, amoxicillin, roxithromycin, cefixime, levofloxacin hydrochloride, cough syrup, dextromethorphan, aminophylline and ambroxol.

Images